Study:
Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms
Rationale:
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the
growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving bevacizumab together with combination chemotherapy may
kill more cancer cells.
Purpose:
This phase II trial is studying how well giving bevacizumab together with several
chemotherapy drugs (combination chemotherapy) works in treating patients with peripheral
T-cell lymphoma or natural killer cell neoplasms.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Lymphoma |
Drug: bevacizumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate |
Phase 2 |
Verified by
Eastern Cooperative Oncology Group
November, 2008
Sponsored by: Eastern Cooperative Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00217425
Study Type: Interventional
Study Design: Treatment, Open Label
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Kristen N. Ganjoo, MD., Study Chair
Ranjana Advani, MD.,